Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genenta Science S.p.A.GNTA · Entity 7215 | Director · Chief Executive Officer · 10% owner | March 30, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genenta Science S.p.A.
Report date March 30, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2035-12-31 | Direct | 100,000 |
Reported balance
After 2026-03-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-30 · Grant · Acquired 100,000 · Balance 100,000 F1: The stock options vest in equal monthly installments over three years beginning March 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in equal monthly installments over three years beginning March 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2026 Filed May 5, 2026 13:00 UTC | Genenta Science S.p.A. GNTA · Entity 7215 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001493152-26-021237 · ownership.xml · derivative · entry 1 Paracchi Pierluigi · CIK 0001854080 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: American Depositary Shares · 100,000 shares Expires 2035-12-31 F1 · derivative.exercise_date: The stock options vest in equal monthly installments over three years beginning March 30, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.